• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Blood Cancer - Pipeline Review, H2 2012 Product Image

Blood Cancer - Pipeline Review, H2 2012

  • Published: December 2012
  • 740 pages
  • Global Markets Direct

Blood Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Blood Cancer - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Blood Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Blood Cancer. Blood Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Blood Cancer.
- A review of the Blood Cancer products under development by companies and universities/research institutes based on information derived READ MORE >

2
List of Tables 15
List of Figures 27
Introduction 28
REPORT COVERAGE 28
Blood Cancer Overview 29
Therapeutics Development 30
An Overview of Pipeline Products for Blood Cancer 30
Blood Cancer Therapeutics under Development by Companies 32
Blood Cancer Therapeutics under Investigation by Universities/Institutes 51
Late Stage Products 71
Comparative Analysis 71
Mid Clinical Stage Products 72
Comparative Analysis 72
Early Clinical Stage Products 73
Comparative Analysis 73
Discovery and Pre-Clinical Stage Products 74
Comparative Analysis 74
Blood Cancer Therapeutics – Products under Development by Companies 75
Blood Cancer Therapeutics – Products under Investigation by Universities/Institutes 113
Companies Involved in Blood Cancer Therapeutics Development 190
Bristol-Myers Squibb Company 190
Genzyme Corporation 191
Johnson & Johnson 192
Boehringer Ingelheim GmbH 193
F. Hoffmann-La Roche Ltd. 194
Kyowa Hakko Kirin Co., Ltd. 195
Abbott Laboratories 196
Amgen Inc. 197
Sanofi-Aventis 198
AstraZeneca PLC 199
Eli Lilly and Company 200
Viralytics Ltd. 201
Athersys, Inc. 202
GlaxoSmithKline plc 203
Seattle Genetics, Inc. 204
Genentech, Inc. 205
MedImmune LLC 206
Gilead Sciences, Inc. 207
Biotest AG 208
Daiichi Sankyo Company, Ltd 209
medac GmbH 210
Merck & Co., Inc. 211
AbGenomics International, Inc. 212
Emergent BioSolutions Inc. 213
Lentigen Corporation 214
Gamida Cell Ltd. 215
Infinity Pharmaceuticals, Inc. 216
BioLineRx, Ltd. 217
Amorfix Life Sciences Ltd. 218
DNAPrint Genomics, Inc. 219
Piramal Healthcare Limited 220
Celltrion, Inc. 221
Bio-Path Holdings, Inc. 222
BioSante Pharmaceuticals, Inc. 223
ZIOPHARM Oncology, Inc. 224
Millennium Pharmaceuticals, Inc. 225
Novartis AG 226
Astellas Pharma Inc. 227
BioMarin Pharmaceutical Inc. 228
Chong Kun Dang Pharmaceutical 229
Daewoong Pharmaceutical Co., Ltd. 230
Gedeon Richter Plc. 231
ImmunoGen, Inc. 232
Nippon Shinyaku Co., Ltd. 233
Ono Pharmaceutical Co., Ltd. 234
Pfizer Inc. 235
Sigma-Tau S.p.A. 236
SuperGen, Inc. 237
Telik, Inc. 280
TopoTarget A/S 281
Mundipharma International Limited 282
Case Comprehensive Cancer Center 283
Axelar AB 345
Proacta, Inc. 346
Cornerstone Pharmaceuticals, Inc. 347
Omnitura Therapeutics Inc. 348
Advenchen Laboratories, LLC 349
AndroScience Corporation 350
Onconova Therapeutics, Inc 351
MolMed S.p.A. 352
TcL Pharma SAS 353
Immune System Therapeutics Ltd. 354
Syndax Pharmaceuticals, Inc. 355
Concert Pharmaceuticals, Inc. 356
NOXXON Pharma AG 357
Fate Therapeutics, Inc. 358
Morphogenesis, Inc. 359
Esperance Pharmaceuticals, Inc. 360
Omeros Corporation 361
Transtech Pharma, Inc. 362
Y's Therapeutics Co., Ltd. 363
Xencor, Inc. 364
Acetylon Pharmaceuticals, Inc. 365
Oncolys BioPharma Inc. 366
iBio, Inc. 367
Tragara Pharmaceuticals, Inc. 368
Cellceutix Corporation 369
PharmaMar, S.A. 370
Kiadis Pharma B.V. 371
VentiRx Pharmaceuticals, Inc. 372
KaloBios Pharmaceuticals, Inc. 373
AmpliMed Corporation 374
AB Science 375
Aprea AB. 376
Kinex Pharmaceuticals, LLC 377
Biokine Therapeutics Ltd. 378
Cylene Pharmaceuticals, Inc. 379
GlycoMimetics, Inc. 380
Lipopharma 381
Biothera 382
Nereus Pharmaceuticals, Inc. 383
TaiGen Biotechnology Co., Ltd. 384
AVEO Pharmaceuticals, Inc. 385
Lytix Biopharma AS 386
TRACON Pharmaceuticals, Inc. 387
TheraCarb Inc. 388
KAHR medical Ltd. 389
TikoMed AB 390
Keystone Nano, Inc. 391
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. 392
Centocor Ortho Biotech, Inc. 393
Advanced Cancer Therapeutics 394
Elara Pharmaceuticals GmbH 395
Sigma-Tau Pharmaceuticals, Inc. 396
Dynamix Pharmaceuticals Ltd. 397
Cancer Therapeutics CRC Pty Ltd 398
LFB Biotechnologies, S.A.S.U. 399
Interprotein Corporation 400
EpiZyme, Inc. 401
Jiangsu Kanion Pharmaceutical Co., Ltd. 402
Kyowa Hakko Kirin Pharma, Inc. 403
KAEL-GemVax 404
Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.,Ltd. 405
iCeutica, Inc. 406
Errant Gene Therapeutics, LLC 407
Mebiopharm Co., Ltd. 408
Polaris Group 409
Gliknik, Inc. 410
XBiotech USA, Inc. 411
IkerChem S.L. 412
ImQuest Life Sciences 413
Immunovative Therapies, Ltd. 414
Herbert Irving Comprehensive Cancer Center 415
Advancell 416
Blood Cancer – Therapeutics Assessment 417
Assessment by Monotherapy Products 417
Assessment by Combination Products 418
Assessment by Route of Administration 419
Assessment by Molecule Type 421
Drug Profiles 424
perifosine - Drug Profile 424
Product Description 424
Mechanism of Action 424
R&D Progress 424
StemEx - Drug Profile 427
Product Description 427
Mechanism of Action 427
R&D Progress 427
obinutuzumab - Drug Profile 428
Product Description 428
Mechanism of Action 428
R&D Progress 428
ixazomib citrate - Drug Profile 429
Product Description 429
Mechanism of Action 429
R&D Progress 429
masitinib - Drug Profile 490
Product Description 490
Mechanism of Action 490
R&D Progress 490
Velcade + Thalidomide + Dexamethasone - Drug Profile 492
Product Description 492
Mechanism of Action 492
R&D Progress 492
RG-7159 + Chlorambucil - Drug Profile 494
Product Description 494
Mechanism of Action 494
R&D Progress 494
Masitinib + Bortezomib + Dexamethasone - Drug Profile 552
Product Description 552
Mechanism of Action 552
R&D Progress 552
calaspargase pegol - Drug Profile 554
Product Description 554
Mechanism of Action 554
R&D Progress 554
Allogeneic Stem Cell Transplantation - Drug Profile 555
Product Description 555
Mechanism of Action 555
R&D Progress 555
Blood Cancer Therapeutics – Drug Profile Updates 556
Blood Cancer Therapeutics – Discontinued Products 604
Blood Cancer Therapeutics - Dormant Products 630
Blood Cancer – Product Development Milestones 728
Featured News & Press Releases 728
Nov 20, 2012: Acetylon Pharma To Present Data On ACY-1215 Development Programs At 54th Annual Meeting Of American Society Of Hematology 728
Nov 20, 2012: Acetylon Pharma To Present Data On ACY-1215 Development Programs At 54th Annual Meeting Of American Society Of Hematology 730
Nov 14, 2012: Bio-Path Completes Fourth Cohort In Phase I Clinical Trial Of Liposomal Grb-2 In Leukemia 732
Nov 13, 2012: Navidea Announces PDUFA Goal Date For Lymphoseek New Drug Application Resubmission 733
Nov 13, 2012: Talon Therapeutics Presents Phase II Data On Marqibo At 2012 Chemotherapy Foundation Symposium 734
Nov 09, 2012: ProNAi Presents Encouraging Phase I Study Results Of PNT2258 At Cancer Meeting 734
Nov 08, 2012: Stemline Therapeutics's SL-401 Induces Complete Response In Patient With Drug-refractory Plasmacytoid Dendritic Cell Neoplasm 735
Nov 07, 2012: BioLineRx To Present Data On BL-8040 For Treatment Of Leukemia And Other Types Of Hematological Cancer At 2012 ASH Annual Meeting 736
Nov 07, 2012: BioLineRx To Present Data On BL-8040 For Treatment Of Leukemia And Other Types Of Hematological Cancer At 2012 ASH Annual Meeting 736
Nov 07, 2012: Patrys Enrolls First Patient In Phase I/IIa PAT-SM6 Multiple Myeloma Trial 737
Appendix 739
Methodology 739
Coverage 739
Secondary Research 739
Primary Research 739
Expert Panel Validation 739
Contact Us 740
Disclaimer 740

List of Tables
Number of Products Under Development for Blood Cancer, H2 2012 30
Products under Development for Blood Cancer – Comparative Analysis, H2 2012 31
Number of Products under Development by Companies, H2 2012 33
Number of Products under Development by Companies, H2 2012 (Contd..1) 34
Number of Products under Development by Companies, H2 2012 (Contd..2) 35
Number of Products under Development by Companies, H2 2012 (Contd..3) 36
Number of Products under Development by Companies, H2 2012 (Contd..4) 37
Number of Products under Development by Companies, H2 2012 (Contd..5) 38
Number of Products under Development by Companies, H2 2012 (Contd..6) 39
Number of Products under Development by Companies, H2 2012 (Contd..7) 40
Number of Products under Development by Companies, H2 2012 (Contd..8) 41
Number of Products under Development by Companies, H2 2012 (Contd..9) 42
Number of Products under Development by Companies, H2 2012 (Contd..10) 43
Number of Products under Development by Companies, H2 2012 (Contd..11) 44
Number of Products under Development by Companies, H2 2012 (Contd..12) 45
Number of Products under Development by Companies, H2 2012 (Contd..13) 46
Number of Products under Development by Companies, H2 2012 (Contd..14) 47
Number of Products under Development by Companies, H2 2012 (Contd..15) 48
Number of Products under Development by Companies, H2 2012 (Contd..16) 49
Number of Products under Development by Companies, H2 2012 (Contd..17) 50
Number of Products under Investigation by Universities/Institutes, H2 2012 52
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 53
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 54
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 55
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 56
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 57
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 58
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 59
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 60
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 61
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 62
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 63
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 64
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 65
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 66
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 67
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 68
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 69
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 70
Comparative Analysis by Late Stage Development, H2 2012 71
Comparative Analysis by Mid Clinical Stage Development, H2 2012 72
Comparative Analysis by Early Clinical Stage Development, H2 2012 73
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 74
Products under Development by Companies, H2 2012 75
Products under Development by Companies, H2 2012 (Contd..1) 76
Products under Development by Companies, H2 2012 (Contd..2) 77
Products under Development by Companies, H2 2012 (Contd..3) 78
Products under Development by Companies, H2 2012 (Contd..4) 79
Products under Development by Companies, H2 2012 (Contd..5) 80
Products under Development by Companies, H2 2012 (Contd..6) 81
Products under Development by Companies, H2 2012 (Contd..7) 82
Products under Development by Companies, H2 2012 (Contd..8) 83
Products under Development by Companies, H2 2012 (Contd..9) 84
Products under Development by Companies, H2 2012 (Contd..10) 85
Products under Development by Companies, H2 2012 (Contd..11) 86
Products under Development by Companies, H2 2012 (Contd..12) 87
Products under Development by Companies, H2 2012 (Contd..13) 88
Products under Development by Companies, H2 2012 (Contd..14) 89
Products under Development by Companies, H2 2012 (Contd..15) 90
Products under Development by Companies, H2 2012 (Contd..16) 91
Products under Development by Companies, H2 2012 (Contd..17) 92
Products under Development by Companies, H2 2012 (Contd..18) 93
Products under Development by Companies, H2 2012 (Contd..19) 94
Products under Development by Companies, H2 2012 (Contd..20) 95
Products under Development by Companies, H2 2012 (Contd..21) 96
Products under Development by Companies, H2 2012 (Contd..22) 97
Products under Development by Companies, H2 2012 (Contd..23) 98
Products under Development by Companies, H2 2012 (Contd..24) 99
Products under Development by Companies, H2 2012 (Contd..25) 100
Products under Development by Companies, H2 2012 (Contd..26) 101
Products under Development by Companies, H2 2012 (Contd..27) 102
Products under Development by Companies, H2 2012 (Contd..28) 103
Products under Development by Companies, H2 2012 (Contd..29) 104
Products under Development by Companies, H2 2012 (Contd..30) 105
Products under Development by Companies, H2 2012 (Contd..31) 106
Products under Development by Companies, H2 2012 (Contd..32) 107
Products under Development by Companies, H2 2012 (Contd..33) 108
Products under Development by Companies, H2 2012 (Contd..34) 109
Products under Development by Companies, H2 2012 (Contd..35) 110
Products under Development by Companies, H2 2012 (Contd..36) 111
Products under Development by Companies, H2 2012 (Contd..37) 112
Products under Investigation by Universities/Institutes, H2 2012 113
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 114
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 115
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 116
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 117
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 118
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 119
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 120
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 121
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 122
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 123
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 124
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 125
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 126
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 127
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 128
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 129
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 130
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 131
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 132
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 133
Products under Investigation by Universities/Institutes, H2 2012 (Contd..21) 134
Products under Investigation by Universities/Institutes, H2 2012 (Contd..22) 135
Products under Investigation by Universities/Institutes, H2 2012 (Contd..23) 136
Products under Investigation by Universities/Institutes, H2 2012 (Contd..24) 137
Products under Investigation by Universities/Institutes, H2 2012 (Contd..25) 138
Products under Investigation by Universities/Institutes, H2 2012 (Contd..26) 139
Products under Investigation by Universities/Institutes, H2 2012 (Contd..27) 140
Products under Investigation by Universities/Institutes, H2 2012 (Contd..28) 141
Products under Investigation by Universities/Institutes, H2 2012 (Contd..29) 142
Products under Investigation by Universities/Institutes, H2 2012 (Contd..30) 143
Products under Investigation by Universities/Institutes, H2 2012 (Contd..31) 144
Products under Investigation by Universities/Institutes, H2 2012 (Contd..32) 145
Products under Investigation by Universities/Institutes, H2 2012 (Contd..33) 146
Products under Investigation by Universities/Institutes, H2 2012 (Contd..34) 147
Products under Investigation by Universities/Institutes, H2 2012 (Contd..35) 148
Products under Investigation by Universities/Institutes, H2 2012 (Contd..36) 149
Products under Investigation by Universities/Institutes, H2 2012 (Contd..37) 150
Products under Investigation by Universities/Institutes, H2 2012 (Contd..38) 151
Products under Investigation by Universities/Institutes, H2 2012 (Contd..39) 152
Products under Investigation by Universities/Institutes, H2 2012 (Contd..40) 153
Products under Investigation by Universities/Institutes, H2 2012 (Contd..41) 154
Products under Investigation by Universities/Institutes, H2 2012 (Contd..42) 155
Products under Investigation by Universities/Institutes, H2 2012 (Contd..43) 156
Products under Investigation by Universities/Institutes, H2 2012 (Contd..44) 157
Products under Investigation by Universities/Institutes, H2 2012 (Contd..45) 158
Products under Investigation by Universities/Institutes, H2 2012 (Contd..46) 159
Products under Investigation by Universities/Institutes, H2 2012 (Contd..47) 160
Products under Investigation by Universities/Institutes, H2 2012 (Contd..48) 161
Products under Investigation by Universities/Institutes, H2 2012 (Contd..49) 162
Products under Investigation by Universities/Institutes, H2 2012 (Contd..50) 163
Products under Investigation by Universities/Institutes, H2 2012 (Contd..51) 164
Products under Investigation by Universities/Institutes, H2 2012 (Contd..52) 165
Products under Investigation by Universities/Institutes, H2 2012 (Contd..53) 166
Products under Investigation by Universities/Institutes, H2 2012 (Contd..54) 167
Products under Investigation by Universities/Institutes, H2 2012 (Contd..55) 168
Products under Investigation by Universities/Institutes, H2 2012 (Contd..56) 169
Products under Investigation by Universities/Institutes, H2 2012 (Contd..57) 170
Products under Investigation by Universities/Institutes, H2 2012 (Contd..58) 171
Products under Investigation by Universities/Institutes, H2 2012 (Contd..59) 172
Products under Investigation by Universities/Institutes, H2 2012 (Contd..60) 173
Products under Investigation by Universities/Institutes, H2 2012 (Contd..61) 174
Products under Investigation by Universities/Institutes, H2 2012 (Contd..62) 175
Products under Investigation by Universities/Institutes, H2 2012 (Contd..63) 176
Products under Investigation by Universities/Institutes, H2 2012 (Contd..64) 177
Products under Investigation by Universities/Institutes, H2 2012 (Contd..65) 178
Products under Investigation by Universities/Institutes, H2 2012 (Contd..66) 179
Products under Investigation by Universities/Institutes, H2 2012 (Contd..67) 180
Products under Investigation by Universities/Institutes, H2 2012 (Contd..68) 181
Products under Investigation by Universities/Institutes, H2 2012 (Contd..69) 182
Products under Investigation by Universities/Institutes, H2 2012 (Contd..70) 183
Products under Investigation by Universities/Institutes, H2 2012 (Contd..71) 184
Products under Investigation by Universities/Institutes, H2 2012 (Contd..72) 185
Products under Investigation by Universities/Institutes, H2 2012 (Contd..73) 186
Products under Investigation by Universities/Institutes, H2 2012 (Contd..74) 187
Products under Investigation by Universities/Institutes, H2 2012 (Contd..75) 188
Products under Investigation by Universities/Institutes, H2 2012 (Contd..76) 189
Bristol-Myers Squibb Company, H2 2012 190
Genzyme Corporation, H2 2012 191
Johnson & Johnson, H2 2012 192
Boehringer Ingelheim GmbH, H2 2012 193
F. Hoffmann-La Roche Ltd., H2 2012 194
Kyowa Hakko Kirin Co., Ltd., H2 2012 195

List of Figures
Number of Products under Development for Blood Cancer, H2 2012 30
Products under Development for Blood Cancer – Comparative Analysis, H2 2012 31
Products under Development by Companies, H2 2012 32
Products under Investigation by Universities/Institutes, H2 2012 51
Late Stage Products, H2 2012 71
Mid Clinical Stage Products, H2 2012 72
Early Clinical Stage Products, H2 2012 73
Discovery and Pre-Clinical Stage Products, H2 2012 74
Assessment by Monotherapy Products, H2 2012 417
Assessment by Combination Products, H2 2012 418
Assessment by Route of Administration, H2 2012 419
Assessment by Stage and Route of Administration, H2 2012 420
Assessment by Molecule Type, H2 2012 421
Assessment by Stage and Molecule Type, H2 2012 422

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos